Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$97.83 USD

97.83
16,833,817

-0.40 (-0.41%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $97.76 -0.07 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (151 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Zacks Equity Research

DOCS Stock Up in Pre-Market Post Q1 Earnings Beat, Gross Margin Down

by Zacks Equity Research

Doximity beats first-quarter fiscal 2026 estimates with double-digit revenue growth and lifts its full-year forecast.

Zacks Equity Research

AMN Stock Slips Despite Q2 Earnings & Revenue Beat, Margins Down

by Zacks Equity Research

AMN Healthcare tops second-quarter 2025 earnings and revenue forecasts, but margins and segment sales face continued pressure.

Zacks Equity Research

Solventum Stock Gains on Q2 Earnings & Revenue Beat, Margins Improve

by Zacks Equity Research

SOLV jumps 5% as Q2 earnings and revenues beat estimates; EPS outlook raised on broad-based segment growth.

Sridatri Sarkar headshot

Abbott's EPD Growth Beats Market Trends: Here's How to Play the Stock

by Sridatri Sarkar

Abbott outpaces market trends as EPD sales surge, fueled by double-digit growth, biosimilar approvals and strong product demand.

Zacks Equity Research

TEM's Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market

by Zacks Equity Research

Tempus AI posts a narrower Q2 loss and an 89.6% revenue surge, driven by genomics growth and new oncology-focused product launches.

Zacks Equity Research

XRAY Stock Rises on Q2 Earnings & Revenues Beat, Adjusted Margins Up

by Zacks Equity Research

DENTSPLY SIRONA tops Q2 earnings estimates with margin gains, but revenue declines and U.S. weakness persists.

Zacks Equity Research

BD Stock Gains in Pre-Market Following Q3 Earnings Beat, Margins Up

by Zacks Equity Research

BDX tops third-quarter fiscal 2025 earnings and margin estimates, with strong results from its Medical and Interventional segments.

Zacks Equity Research

ZBH Stock Gains On Q2 Earnings and Revenue Beat, '25 EPS View Up

by Zacks Equity Research

Zimmer Biomet gains as Q2 earnings and revenues top estimates; full-year EPS guidance raised on strong segment growth.

Zacks Equity Research

Investors Heavily Search Boston Scientific Corporation (BSX): Here is What You Need to Know

by Zacks Equity Research

Zacks.com users have recently been watching Boston Scientific (BSX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Equity Research

MCK Stock Down Despite Q1 Earnings Beat & Raised '26 EPS View

by Zacks Equity Research

McKesson beats on Q1 earnings and raises FY26 EPS view, but shares slip as gross margin narrows and spin-off plans weigh on investors' sentiment.

Zacks Equity Research

STE Beats on Q1 Earnings and Revenues, Raises '26 Sales View

by Zacks Equity Research

STERIS posts 15% EPS growth and raises FY26 revenue outlook, with all segments showing solid year-over-year gains.

Zacks Equity Research

ACB Stock Down as Q1 Earnings Miss Estimates, Revenues Up Y/Y

by Zacks Equity Research

Aurora Cannabis stock slips after Q1 earnings miss, but revenue climbs 17.5% year over year on strong global medical cannabis demand.

Zacks Equity Research

Avanos Medical Stock Down as Q2 Earnings Miss Estimates, Margins Down

by Zacks Equity Research

AVNS shares dip 12% as Q2 earnings miss estimates, margins shrink, and tariff pressures weigh on profitability.

Zacks Equity Research

QuidelOrtho Stock Gains Following Q2 Earnings Beat, Margins Expand

by Zacks Equity Research

QDEL stock rises 12.8% after Q2 earnings beat. Adjusted margins improve amid soft revenue and ongoing business headwinds.

Zacks Equity Research

DaVita Stock Down Despite Q2 Earnings Beat, Gross Margin Expands

by Zacks Equity Research

DVA reports strong second-quarter 2025 results with earnings and revenue beat, along with a boost in gross margin, driven by core operations.

Zacks Equity Research

MASI Stock Slips Despite Q2 Earnings and Revenue Beat, Margins Expand

by Zacks Equity Research

Masimo's second-quarter 2025 performance beats earnings and revenue estimates, expands margins and lifts 2025 outlook.

Zacks Equity Research

FMS Stock Rises as Q2 Earnings Beat Estimates, Revenues Gain Y/Y

by Zacks Equity Research

Fresenius Medical stock rises as Q2 earnings and revenues top estimates, driven by solid organic growth and expanding margins.

Zacks Equity Research

CLOV Q2 Earnings In Line, Stock Falls on Raised Insurance BER View

by Zacks Equity Research

Clover Health's Q2 revenues rise 34%, but raised Insurance BER guidance and margin pressures cause shares to tumble post-earnings.

Zacks Equity Research

COR Q3 Earnings & Revenues Beat Estimates, '25 EPS View Raised

by Zacks Equity Research

Cencora posts strong Q3 results with earnings and revenues surpassing estimates; raises FY25 EPS guidance on robust U.S. segment growth.

Zacks Equity Research

CRL Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 View

by Zacks Equity Research

Charles River shares jump 9.3% pre-market after Q2 earnings and revenues beat estimates. The company raises its 2025 outlook.

Zacks Equity Research

Bio-Techne Q4 Earnings Beat Estimates, Gross Margin Down, Stock Falls

by Zacks Equity Research

TECH tops Q4 EPS estimates and posts solid revenues, but shrinking margins and operating loss drag shares lower.

Zacks Equity Research

HIMS Stock Plunges Following Q2 Earnings Miss, Gross Margin Down

by Zacks Equity Research

Hims & Hers misses second-quarter 2025 EPS and revenue estimates as gross margin narrows, despite strong online sales and subscriber growth.

Zacks Equity Research

INSP Stock Plunges Despite Q2 Earnings Beat, Gross Margin Contracts

by Zacks Equity Research

Inspire Medical tops second-quarter 2025 earnings estimates and posts solid revenue growth, but trims 2025 guidance amid margin pressure.

Zacks Equity Research

Henry Schein Stock Falls on Q2 Earnings Miss, Revenues Top

by Zacks Equity Research

HSIC slides after Q2 EPS misses estimates by 6.8%. Revenues beat with 3.2% growth and strength across key segments.

Zacks Equity Research

AVTR Stock Declines as Q2 Earnings Miss Estimates, Revenues Down Y/Y

by Zacks Equity Research

Avantor stock dips more than 15% as Q2 EPS missed estimates, revenue declines year over year and lowers full-year guidance.